Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunological Synapses | 1 | 2025 | 26 | 0.970 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 60 | 0.940 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 102 | 0.920 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 479 | 0.550 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2025 | 790 | 0.530 |
Why?
|
| Immunotherapy | 1 | 2016 | 658 | 0.380 |
Why?
|
| T-Lymphocytes | 5 | 2025 | 1678 | 0.360 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 262 | 0.270 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.240 |
Why?
|
| CD28 Antigens | 1 | 2025 | 78 | 0.240 |
Why?
|
| Neoplasms | 1 | 2016 | 2753 | 0.200 |
Why?
|
| Sarcoma | 1 | 2024 | 197 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 235 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 497 | 0.180 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.170 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 3290 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 93 | 0.170 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 177 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 426 | 0.160 |
Why?
|
| Ependymoma | 1 | 2020 | 134 | 0.160 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 187 | 0.150 |
Why?
|
| Medulloblastoma | 1 | 2020 | 338 | 0.140 |
Why?
|
| Genetic Engineering | 1 | 2016 | 159 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 271 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2025 | 4511 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1222 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 874 | 0.070 |
Why?
|
| Humans | 6 | 2025 | 122296 | 0.060 |
Why?
|
| Vidarabine | 1 | 2024 | 79 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 122 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2023 | 60 | 0.050 |
Why?
|
| Animals | 3 | 2020 | 33721 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 422 | 0.050 |
Why?
|
| Pyrroles | 1 | 2023 | 177 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12045 | 0.050 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 65 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 297 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 501 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 181 | 0.040 |
Why?
|
| Transgenes | 1 | 2020 | 330 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 570 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1076 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 650 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 741 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 386 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 283 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1732 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1579 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2441 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1272 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 5963 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 2933 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4282 | 0.020 |
Why?
|
| Male | 2 | 2024 | 59522 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 18785 | 0.020 |
Why?
|
| Female | 2 | 2024 | 64883 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 12302 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 25640 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 13777 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 28733 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 17546 | 0.010 |
Why?
|
| Child | 1 | 2020 | 24064 | 0.010 |
Why?
|